TABLE 3.
Comparison of the clinical performance for the detection of csPCa of Proclarix, PSAD and Proclarix density in the patient population with PI‐RADS 3 findings (n = 28).
| Parameter | Proclarix | PSA density | p‐value a | Proclarix density | PSA density | p‐value b |
|---|---|---|---|---|---|---|
| Cut‐off | 10 | 0.15 | ‐ | 0.395 c | 0.043 c | ‐ |
| Sensitivity, % |
100 (100–100) |
67 (29–100) |
0.157 |
100 (100–100) |
100 (100–100) |
1.000 |
| Specificity, % |
14 (0–24) |
82 (66–98) |
<0.001 |
41 (20–61) |
14 (0–28) |
0.034 |
| NPV, % |
100 (100–100) |
90 (77–100) |
0.157 |
100 (100–100) |
100 (100–100) |
1.000 |
| PPV, % |
24 (7–41) |
50 (15–85) |
0.012 |
32 (11–52) |
24 (7–41) |
0.034 |
a
Comparison between Proclarix and PSA density.
b
Comparison between Proclarix density and PSA density at optimal cut‐offs.
c
Optimized cut‐offs for this patient population with PI‐RADS 3 findings.